Amgen, Kyowa Kirin Ink $1.25B Deal for Developing KHK4083 In Skin Disorders

  • Amgen Inc AMGN and Kyowa Kirin Co Ltd KYKOF have agreed to jointly develop and commercialize KHK4083, Kyowa Kirin's Phase 3-ready anti-OX40 fully human monoclonal antibody in development for atopic dermatitis, with potential in other autoimmune diseases.
  • In February, Kyowa Kirin announced positive results from a Phase 2 study of KHK4083 in patients with moderate-to-severe atopic dermatitis.
  • In exchange for an upfront of $400 million and milestones worth up to $850 million, Amgen will lead development, manufacturing, and sales outside of Japan for KHK4083.
  • If approved, Kyowa Kirin will co-promote the drug with Amgen in the U.S., with the option to co-promote it in other markets, including some in Europe and Asia.
  • Amgen will host a webcast call today at 8:00 a.m. ET.
  • Price Action: AMGN shares are up 1.9% at $242.54 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsGeneralatopic dermatitisBriefsSkin Disorder
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!